Prednisone can reduce osteoarthritis pain in the short term, but it is not a standard go-to treatment for the condition. Most rheumatology guidelines reserve oral corticosteroids like prednisone for brief flare-ups where inflammation is clearly driving the pain, not for ongoing joint management. The evidence that exists is surprisingly thin for such a commonly prescribed drug, concentrated in a handful of trials focused on hand and knee osteoarthritis. And the side-effect profile, even over just a few weeks, makes the risk-benefit math tighter than many people expect.
How Prednisone Tamps Down OA Pain
Osteoarthritis was once considered purely a “wear and tear” disease, but researchers now recognize that inflammation plays a real role in driving pain and joint damage, at least in a subset of patients. The lining of the joint (the synovium) can become inflamed, producing swelling, warmth, and tenderness that go beyond simple mechanical grinding. Prednisone, a synthetic corticosteroid, works by broadly dialing down the body’s inflammatory machinery. It suppresses the signaling molecules that recruit immune cells to inflamed tissue and slows the production of enzymes that chew up cartilage.
In lab and animal models, this anti-inflammatory action can actually help preserve the structural matrix of cartilage at low doses, by shifting the balance away from tissue-destroying enzymes and toward repair.1PubMed Central. Study of osteoarthritis treatment with anti-inflammatory drugs: cyclooxygenase-2 inhibitor and steroids That sounds encouraging, but there is an important catch: the same effect reverses at higher doses or with prolonged use, and the clinical evidence in humans is far less tidy than the lab data. The gap between what prednisone does to cells in a dish and what it does inside a living, aging joint is one of the central tensions in this area of medicine.
What the Clinical Trials Actually Found
The strongest trial evidence for oral prednisone in osteoarthritis comes from two specific joints: the hand and the knee. In the HOPE trial, published in The Lancet, patients with painful hand osteoarthritis and signs of active synovial inflammation took 10 mg of prednisolone daily for six weeks. (Prednisolone is the active form prednisone converts to in the body; they are clinically interchangeable at equivalent doses.) By week six, finger pain dropped substantially more in the prednisolone group than in the placebo group, with a meaningful gap between the two arms.2PubMed. Efficacy of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial The researchers deliberately selected patients whose joints showed signs of inflammation on imaging, reasoning that those people would benefit most from an anti-inflammatory drug.3Nature Reviews Rheumatology. Short-term prednisolone improves hand OA
For knee osteoarthritis, a separate randomized trial in older adults found a similar pattern. Low-dose oral prednisolone over six weeks produced clinically relevant improvements in knee pain, physical function, and walking distance compared to placebo. The trial also showed reductions in markers of systemic inflammation in the blood, confirming that the drug was doing more than just numbing pain perception.4PubMed. Effect of low-dose oral prednisolone on symptoms and systemic inflammation in older adults with moderate to severe knee osteoarthritis: a randomized placebo-controlled trial
Both trials share a key design feature: they were short. Six weeks of treatment, with follow-up to see whether benefits lingered. This matters because the question most people have is not “does prednisone work for six weeks” but “can I keep taking it.” The trials were never designed to answer that second question, and no one has run a long-duration trial of daily oral prednisone for osteoarthritis, because the side effects make it ethically difficult to justify.
Where It Fits in the Treatment Ladder
If you look at major rheumatology guidelines, oral prednisone for osteoarthritis sits far down the list. The European League Against Rheumatism (EULAR), for example, recommends starting with topical treatments, particularly topical anti-inflammatory gels, before moving to oral painkillers. Their updated guidelines note that intra-articular glucocorticoid injections are generally not recommended for hand osteoarthritis, with a narrow exception for painful interphalangeal joints.5PubMed. 2018 update of the EULAR recommendations for the management of hand osteoarthritis Oral corticosteroids do not even appear as a standard recommendation in most knee or hip OA guidelines.
This does not mean doctors never prescribe it. In practice, a rheumatologist might offer a short course of oral prednisone during a bad flare when other options have not worked or are contraindicated. Someone who cannot take anti-inflammatory drugs because of kidney disease or stomach ulcers, for instance, might get a brief prednisone burst as a bridge. The HOPE trial’s authors framed their results as offering “a new short-term treatment option for patients with hand osteoarthritis who report a flare-up of their disease,” not as a chronic therapy.6The Lancet. Efficacy and safety of oral prednisolone for hand osteoarthritis (HOPE): a randomised, double-blind, placebo-controlled trial The emphasis on “flare-up” is the operative phrase.
What Prednisone Will Not Help
Not all osteoarthritis pain responds to prednisone, even during a course where inflammation is clearly present. A secondary analysis of the HOPE trial found that patients whose pain had neuropathic-like qualities, burning, tingling, or shooting sensations, did not see those symptoms improve with prednisolone. Their inflammatory pain got better, but the nerve-related component persisted.7PubMed Central. Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment This finding is worth knowing, because neuropathic pain is more common in osteoarthritis than many people realize. If your pain has an electric or burning quality, a corticosteroid alone is unlikely to resolve it completely.
Prednisone also does nothing to reverse structural damage. It does not rebuild worn cartilage, grow new bone, or realign a joint. The benefits documented in trials are symptomatic: less pain, better function, reduced swelling. Once the course ends, the underlying disease is still there. Some patients find that pain creeps back after stopping, which creates a temptation to keep refilling the prescription. That temptation is where most of the danger lies.
Side Effects With Short Courses
Even a few weeks of prednisone can produce noticeable side effects. The most common complaints during short courses include trouble sleeping, mood changes, increased appetite, fluid retention, and a noticeable rise in blood sugar. That last one is not trivial. Corticosteroids push blood glucose up in almost everyone, and the effect can be dramatic in people with diabetes. Even after a single corticosteroid injection into a knee joint, blood glucose in patients with controlled diabetes can spike to around 300 mg/dL and remain elevated for several days.8SpringerLink / Clinical Rheumatology. Systemic effects of intra-articular corticosteroids Oral prednisone, which delivers the drug systemically, can cause the same problem on a more sustained basis.
A narrative review of short-term glucocorticoid side effects (treatment under 30 days) found that metabolic disruptions and drug interactions are common enough that clinicians need to actively monitor for them, not simply assume a brief course is consequence-free.9Swiss Medical Weekly. Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach The mood effects deserve special mention. Some people feel euphoric or energized on prednisone; others become anxious, irritable, or emotionally volatile. These effects tend to resolve after stopping the drug, but they can be disconcerting if you are not expecting them.
The Cartilage Question
One of the most debated issues with corticosteroids and osteoarthritis is whether the treatment itself accelerates joint deterioration. The concern is not abstract. A systematic review of lab and animal studies found that corticosteroids display dose-dependent effects on cartilage. At low doses, some corticosteroids appeared to support cartilage cell growth and recovery. At higher doses, the same drugs caused significant cartilage damage and cell death.10PubMed Central. The Effect of Intra-articular Corticosteroids on Articular Cartilage: A Systematic Review The tipping point varied by drug and species, which makes it difficult to draw a clean line for human doses.
A large observational study using data from the Osteoarthritis Initiative looked at this question from a different angle. Among hundreds of patients with knee osteoarthritis who either received intra-articular corticosteroid injections or did not, those who received injections had roughly three times the rate of joint-space narrowing and structural worsening on X-ray. Patients who received repeated injections had even worse outcomes, with hazard ratios climbing higher with continuous use.11Osteoarthritis and Cartilage. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative This study looked at injections rather than oral prednisone, and it was observational, meaning the people getting injections may have had worse joints to begin with. But the signal was strong enough to concern researchers and has fueled a broader reconsideration of how freely corticosteroid injections should be offered for OA.
For oral prednisone, the structural question is less studied. The short trial durations mean we do not have good data on whether a six-week oral course changes the trajectory of joint damage. It is plausible that the anti-inflammatory effect is protective in the short run while the cumulative exposure becomes harmful if repeated. That uncertainty is one reason guidelines keep oral corticosteroids in the “short-term flare” box rather than moving them into routine care.
Bone Loss at Surprisingly Low Doses
The bone effects of prednisone are well established in other conditions, but many osteoarthritis patients do not realize how quickly they can appear. A randomized, placebo-controlled trial in healthy postmenopausal women found that just 5 mg of prednisone per day, a dose many people consider negligible, significantly suppressed multiple markers of bone formation within weeks.12PubMed. Effects of low-dose prednisone on bone metabolism The effect was rapid and consistent across several different markers, suggesting that even low-dose prednisone slows the body’s ability to repair and renew bone tissue.
This is particularly relevant for osteoarthritis patients because they tend to be older and are often already at elevated risk for osteoporosis. A person taking repeated short courses of prednisone over several years for OA flares could accumulate enough corticosteroid exposure to meaningfully weaken their skeleton without ever being on what anyone calls “chronic” therapy. If your doctor prescribes prednisone more than once or twice for OA flares, it is reasonable to ask about bone density screening and whether calcium and vitamin D supplementation makes sense during and after the course.
Tapering Off and What Happens to Your Adrenal Glands
When you take prednisone, your body’s own cortisol production dials down because the drug is doing the job. Stop the drug abruptly and your adrenal glands may not ramp back up immediately, leaving you in a temporary state of cortisol deficiency. Symptoms can include fatigue, weakness, lightheadedness, nausea, and joint pain that may be mistaken for a return of the OA flare.
The traditional teaching was that this adrenal suppression only mattered with higher doses taken for months. More recent evidence challenges that. Studies have shown that even short courses under four weeks, and even doses below 5 mg per day, can suppress the adrenal axis.13PubMed Central. Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice Exogenous glucocorticoids suppress the hormonal signals that tell the adrenal glands to produce cortisol, and this suppression can occur even at doses considered “physiologic.”14European Journal of Internal Medicine. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself
A 2025 study published in JAMA Network Open looked at what happens after patients stop prednisolone following a six-week course. Formal biochemical adrenal insufficiency (measured by a stimulation test) was uncommon, occurring in fewer than 2% of participants. But about a third of participants reported symptoms consistent with adrenal insufficiency, including fatigue and reduced quality of life, even when their cortisol levels technically passed the lab test. Patients in the symptomatic group had lower baseline cortisol levels on average.15JAMA Network Open. Changes in Adrenal Function and Insufficiency Symptoms After Cessation of Prednisolone The practical takeaway: even after a standard OA-length course of prednisone, you may feel lousy for a few weeks after stopping, and that malaise is probably your adrenal glands waking back up, not your OA getting worse.
Most clinicians taper prednisone gradually rather than stopping cold, especially after courses longer than two weeks. The taper gives your adrenal glands time to resume normal production. If you are prescribed a taper schedule, do not skip it or shorten it on your own, even if you feel fine. The consequences of sudden withdrawal are rare but can be serious.
People Who Should Be Especially Cautious
Certain groups face outsized risks from prednisone, even at the low doses used for OA flares:
- Diabetes: Blood glucose rises are nearly universal with corticosteroids. If you have diabetes, your doctor will need to adjust your glucose-lowering medications during the course and for a period afterward. Home monitoring becomes essential.
- Osteoporosis risk: Postmenopausal women, older men, anyone with a history of fragility fractures, or people already on medications that weaken bone should weigh the prednisone benefit against the documented suppression of bone formation.
- Infection risk: Prednisone suppresses immune function. People with chronic infections, those on immunosuppressive drugs for other conditions, or anyone about to undergo surgery should flag this to their prescriber.
- Mental health: A history of depression, anxiety, or steroid-induced mood changes is worth mentioning before starting prednisone. The mood effects are unpredictable and can range from mild to disabling.
- Glaucoma or cataracts: Corticosteroids raise intraocular pressure and accelerate cataract formation. If you have a history of either, even short courses warrant a conversation with your eye doctor.
Oral Prednisone Versus Corticosteroid Injections
If you have been offered a corticosteroid injection into your arthritic joint and are now reading about oral prednisone, you might wonder which approach makes more sense. They are different tools. An injection delivers a high local concentration of corticosteroid directly to the inflamed joint, with relatively less drug reaching the rest of your body. Oral prednisone distributes throughout the bloodstream, which means every tissue is exposed, not just the target joint. For a single painful knee, an injection is usually the more targeted option. For hand osteoarthritis affecting multiple small joints at once, where injecting each one is impractical, an oral course can make more sense.
Injections are not strictly “local” treatments, though. The drug does get absorbed into the bloodstream. Serum cortisol drops within hours of a joint injection and can take one to four weeks to return to normal, sometimes longer depending on the dose and number of joints injected.8SpringerLink / Clinical Rheumatology. Systemic effects of intra-articular corticosteroids So even with an injection, some of the systemic concerns, blood glucose spikes, adrenal suppression, immune effects, still apply, just usually to a lesser degree.
Why Inflammation Status Matters More Than the Diagnosis
One of the clearest themes in the research is that prednisone works best when there is active inflammation to suppress. The HOPE trial deliberately enrolled patients who had signs of synovial inflammation on ultrasound, and that subgroup selection is likely why the results were as clean as they were.3Nature Reviews Rheumatology. Short-term prednisolone improves hand OA Not all osteoarthritis flares involve heavy inflammation. Some are driven more by mechanical factors: a loose body in the joint, a bone spur catching during movement, or simple overuse of a damaged joint. In those situations, a corticosteroid has less to work with.
If you and your doctor are considering a prednisone trial, the decision should ideally be guided by evidence that your joints are actually inflamed. Swelling, warmth, and tenderness on exam are suggestive. Ultrasound or MRI showing synovitis (inflammation of the joint lining) is more definitive. A joint that hurts mostly with loading or movement but does not look swollen or feel warm is less likely to respond to a corticosteroid and more likely to benefit from physical therapy, bracing, or other mechanical interventions. The diagnosis of osteoarthritis alone does not predict who will benefit from prednisone; the presence and degree of inflammation within that diagnosis does.
Cost and the Bigger Treatment Picture
Prednisone is cheap. A six-week course of generic oral prednisone costs very little out of pocket, which makes it attractive compared to newer biologic injections, hyaluronic acid shots, or ongoing use of branded topical anti-inflammatories. A systematic review of cost-effectiveness studies for OA drugs found that intra-articular injections ranged enormously in cost per quality-adjusted life year gained, from a few hundred to tens of thousands of dollars, while oral anti-inflammatory drugs also varied widely depending on the specific agent.16PubMed Central. Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review
But low cost per pill does not mean low total cost if the drug triggers complications. A corticosteroid-induced glucose crisis in a diabetic patient, a fracture accelerated by bone loss, or an emergency room visit for adrenal insufficiency symptoms can all dwarf the savings on the prescription itself. The economic argument for prednisone is only compelling when the clinical argument already holds: short duration, clear inflammatory flare, limited alternatives, and a patient whose risk profile does not tip the balance toward harm.